SEPROXETINE HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H16F3NO.ClH
Molecular Weight	331.76
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.NCC[C@H](OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2

InChI

InChIKey=GMTWWEPBGGXBTO-RSAXXLAASA-N

InChI=1S/C16H16F3NO.ClH/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12;/h1-9,15H,10-11,20H2;1H/t15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H16F3NO
Molecular Weight	295.2995
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1279447
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15886723 | https://www.ncbi.nlm.nih.gov/pubmed/10208643 | https://www.ncbi.nlm.nih.gov/pubmed/8512621

Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI). It is the most important active metabolite of the widely used antidepressant fluoxetine, but little is known about its pharmacological actions. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, a cardiac side effect was noted and development was discontinued.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine transporter 183 Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888	Inhibitor 8504	4544.0 nM [Ki]
Norepinephrine transporter 197 Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888	Inhibitor 8504	6186.0 nM [Ki]
Serotonin transporter 183 Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19014888	Inhibitor 8504	50.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2596

PubMed

Title	Date	PubMed
Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.	2009-01-01	19014888

Patents

Sample Use Guides

In Vivo Use Guide

Rats were treated with Norfluoxetine (0-20mg/kg)

Route of Administration: Other

In Vitro Use Guide

Rat cortical membranes equivalent to 50 mkg of protein were incubated at 37°C for 30 minutes in 2 ml of reaction medium containing the (S)-Norfluoxetine (1-1000nM), 0.1 nM [3Hlparoxetine, 50 mmol/L Tris-HG, pH 7.4, 150 mmol/L NaG, and 5 mmol/L KCl. Fluoxetine at 1 mkM/kg was used to determine nonspecific binding

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:37 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:37 GMT 2025`
Record UNII	K4QYN23H2N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SEPROXETINE HYDROCHLORIDE

Official Name

English

LY-215229 HYDROCHLORIDE

Preferred Name

English

LY215229 HYDROCHLORIDE

Code

English

Seproxetine hydrochloride [WHO-DD]

Common Name

English

SEPROXETINE HCL

Common Name

English

SEPROXETINE HYDROCHLORIDE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C265